Education
MD – Medical School, Universidad Anahuac, Mexico City (1984)
Residency – The University of Texas Health Science Center, San Antonio, Texas (1985-1988)
Fellowship – Children’s Medical Center of Dallas and The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas (1988-1991)
Clinical Fellowship – American Cancer Society (1989-1990)
Research Interests
Development of novel therapies for pediatric solid tumors with special interest in:
- Pediatric melanoma
- Soft tissue sarcomas
- Pediatric gastrointestinal stromal tumors
Selected Publications
Pappo full list of publications
Nagel MB, Perrino MR, Nuccio R, Blake AK, Harrison L, Nichols KE, Pappo AS. Germline genomic findings in children and young adults with melanocytic tumors. Pediatr Blood Cancer Jul;70(7):e30361, 2023. doi: 10.1002/pbc.30361. Epub 2023 Apr 19. PMID: 37073685
Pappo AS, Karol SE, Bertrand KC. Top advances of the year: Pediatric oncology. Cancer Oct;128(20):3593-3596, 2022. doi: 10.1002/cncr.34425. Epub 2022 Sep 8. PMID: 36074012
Pappo AS, McPherson V, Pan H, Wang F, Wang L, Wright T, Hussong M, Hawkins D, Kaste SC, Davidoff AM, Bahrami A. A prospective, comprehensive registry that integrates the molecular analysis of pediatric and adolescent melanocytic lesions. Cancer Oct 15;127(20):3825-3831, 2021. doi: 10.1002/cncr.33750. Epub 2021 Jul 6. PMID: 34228365; PMCID: PMC8478797
Ortiz MV, Gerdemann U, Raju SG, Henry D, Smith S, Rothenberg SM, Cox MC, Proust S, Bender JG, Frazier AL, Anderson P, Pappo AS. Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations. JCO Precis Oncol Apr 14;4:PO.19.00401, 2020. doi: 10.1200/PO.19.00401. PMID: 32923911; PMCID: PMC7450975
Furman WL, Federico SM, McCarville MB, Shulkin BL, Davidoff AM, Krasin MJ, Sahr N, Sykes A, Wu J, Brennan RC, Bishop MW, Helmig S, Stewart E, Navid F, Triplett B, Santana VM, Bahrami A, Anthony G, Yu AL, Hank J, Gillies SD, Sondel PM, Leung WH, Pappo AS. A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma. Clin Cancer Res Nov 1;25(21):6320-6328, 2019. doi: 10.1158/1078-0432.CCR-19-1452. Epub 2019 Oct 10. PMID: 31601569; PMCID: PMC6825564
Rodriguez-Galindo C, Krailo MD, Krasin MJ, Huang L, McCarville MB, Hicks J, Pashankar F, Pappo AS. Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study. J Clin Oncol Dec 10;37(35):3369-3376, 2019. doi: 10.1200/JCO.19.01276. Epub 2019 Sep 25. Erratum in: J Clin Oncol May 10;39(14):1602, 2021. PMID: 31553639; PMCID: PMC6920031
Lucas JT Jr, Pappo AS. Optimal dosing of cyclophosphamide in rhabdomyosarcoma: It's complicated. Cancer Sep 15;125(18):3107-3110, 2019. doi: 10.1002/cncr.32205. Epub 2019 Jun 7. PMID: 31174230; PMCID: PMC8721594
DuBois SG, Laetsch TW, Federman N, Turpin BK, Albert CM, Nagasubramanian R, Anderson ME, Davis JL, Qamoos HE, Reynolds ME, Cruickshank S, Cox MC, Hawkins DS, Mascarenhas L, Pappo AS. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. Cancer Nov 1;124(21):4241-4247, 2018. doi: 10.1002/cncr.31701. Epub 2018 Sep 11. PMID: 30204247; PMCID: PMC6263791
Halalsheh H, McCarville MB, Neel M, Reynolds M, Cox MC, Pappo AS. Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma. Pediatr Blood Cancer Oct;65(10):e27271, 2018. doi: 10.1002/pbc.27271. Epub 2018 Jun 12. PMID: 29893456
Last update: August 2023